Clinical Trial Opportunity: Have Hyperuricemia?
LG Chem is looking for 350 participants across several different regions to try out Tigulixostat, a medication designed to stop the enzyme that metabolizes purines. Purines are the compounds that become uric acid. When built up over time, this can cause hyperuricemia, which is the root cause of gout.
Tigulixostat is classified as a xanthine oxidase inhibitor, similar to allopurinol or febuxostat. The Phase 3 clinical trial intends to test the drug’s effectiveness for six months in people with hyperuricemia, versus those who are given a placebo.
Find out here if you are eligible to participate
|